Abstract. The expression level and roles of microRNA-497 (miR-497) have been frequently reported in previous studies on cancer. However, its expression, function and associated molecular mechanisms in retinoblastoma remain unknown. In the present study, miR-497 expression levels in human retinoblastoma tissues, normal retinal tissues and retinoblastoma cell lines were determined using reverse transcription-quantitative polymerase chain reaction. In addition, a Cell Counting Kit-8 assay, cell migration assay, cell invasion assay, western blot analysis and Dual-Luciferase reporter assay were used to explore the expression, functions and molecular mechanisms of miR-497 in human retinoblastoma. It was demonstrated that miR-497 was significantly downregulated in retinoblastoma tissues and cell lines compared with normal retinal tissues. Ectopic expression of miR-497 decreased the proliferation, migration and invasion of retinoblastoma cells. Furthermore, VEGFA was verified as a potential direct target of miR-497 in vitro. Taken together, the results indicate that miR-497 functions as a tumor suppressor in the carcinogenesis and progression of retinoblastoma via targeting VEGFA. miR-497 should be investigated as a potential therapeutic target for the treatment of retinoblastoma.

Introduction

Retinoblastoma, the most common primary malignancy in the retina, usually occurs in childhood and accounts for 2-4% of all childhood malignancies. The morbidity rate is ~1:15,000-1:20,000 in children <5 years of age (1,2). In 2015, it was estimated that there were 2,580 new cases in the United States (3). Various factors are involved in the carcinogenesis and development of retinoblastoma, including genetic and epigenetic alterations to oncogenes and tumor suppressor genes, and a large number of these have previously been demonstrated to regulate cell growth, the cell cycle and apoptosis (4,5). In developed countries, >95% of patients with retinoblastoma have a good prognosis. However, in patients with advanced disease, the prognosis remains unsatisfactory due to metastasis to distant organs (6,7). Currently, the main therapeutic strategies for patients with retinoblastoma are surgery (removal of the eyes), thermotherapy, cryotherapy, chemotherapy (systemic and local delivery) and radiotherapy (8). Despite advances in the development of therapeutic strategies for patients with retinoblastoma, a proportion of retinoblastoma cases respond only transiently to these treatments (9). Given this, it is necessary to further explore the molecular mechanisms underlying the initiation and progression of retinoblastoma and to develop effective treatments, including molecular targeted therapy, a novel potential option for individualized therapy.

Accumulating evidence suggests that abnormal expression levels of a variety of microRNAs (miRNAs) are often present in various types of human cancer, including retinoblastoma, indicating the potential functions of miRNAs in carcinogenesis and cancer progression (10-12). miRNAs, which are a class of single-stranded, short (~23 bases in length) and non-protein-coding RNAs, act as negative regulators of their target mRNAs by binding to the 3' untranslated region (UTR) of the mRNA, resulting in target degradation or translational repression (5,13). An increasing number of studies have revealed that miRNAs are involved in a wide variety of physiological and pathological processes, including cell proliferation, the cell cycle, apoptosis, differentiation, angiogenesis, migration, invasion and metastasis (14,15). miRNAs may act as oncogenes or tumor suppressors in cancer, depending on their target mRNA (16). miRNAs that are downregulated in cancer normally act as tumor suppressors, whereas upregulated miRNAs usually act as oncogenes (17). Therefore, the identification of target miRNAs of miRNAs is important in order to further understand the roles of miRNAs in cancer initiation and progression. Due to the regulatory functions of miRNAs in cancer initiation and progression, targeting of miRNAs should be investigated as a novel therapeutic strategy.

Key words: microRNA-497, retinoblastoma, vascular endothelial growth factor A, targeted therapy
miR-497, a member of the miR-15/16/195/424/497 family, has been demonstrated to be aberrantly expressed in numerous types of cancer (18). However, its expression, function and associated molecular mechanisms in retinoblastoma have not been previously studied. The results of the present study indicate that miR-497 is downregulated in human retinoblastoma tissues and cell lines, and that ectopic expression of miR-497 can suppress proliferation, migration and invasion in retinoblastoma cells via blocking vascular endothelial growth factor A (VEGFA). These findings indicate that miR-497 may be a potential targeted therapy for retinoblastoma.

Materials and methods

**Human retinoblastoma tissue samples.** The present study was approved by the Human Subjects Committee of Xi'an XD Group Hospital (Xi'an, China). Written informed consent was also obtained from all patients prior to enrollment in the study. In total, 23 human retinoblastoma tissue samples and 5 normal retinal tissues were used in the present study, and were obtained from patients with retinoblastoma who had undergone surgery in Xi'an XD Group Hospital. These patients had not received thermotherapy, cryotherapy, chemotherapy or radiotherapy prior to surgery. Tissues were immediately snap-frozen in liquid nitrogen and transferred to a -80°C freezer until use.

**Cell culture.** The Y79 and WERI-Rb-1 human retinoblastoma cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in Gibco RPMI-1640 medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% Gibco fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in humidified atmosphere of 5% CO₂ at 37°C.

**Cell transfection.** Mature miR-497 mimics and the negative control miRNA (NC) were synthesized and purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). To assess the functions of miR-497 in retinoblastoma, miR-497 mimics and NC were transfected into Y79 and WERI-Rb-1 cells. Prior to transfection for 12 h, cells were seeded on 6-well plates at a density of 8x10⁴ and cultured in RPMI-1640 without FBS and antibiotics at 37°C.

**RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Total RNA samples from retinoblastoma tissue samples, normal retinal tissues and retinoblastoma cell lines were isolated using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Total RNA was reverse transcribed to cDNA using a PrimeScript RT Reagent kit (Takara Biotechnology, Co., Ltd., Dalian, China). RT-qPCR analyses were conducted to detect the expression levels of VEGFA mRNA using Power SYBR-Green PCR Master Mix (Thermo Fisher Scientific, Inc.). The thermocycling conditions of qPCR were as follows: 95°C for 10 min; 40 cycles of 95°C for 15 sec; and 60°C for 1 min. This reaction included 2 µl cDNA (200 ng), 2 µl forward primer and 2 µl reverse primer.

**miR-497 expression was determined using a SYBR Premix Ex Taq mix (Takara Biotechnology, Co., Ltd.). This stage was performed with cycling conditions as follows: 5 min at 95°C; followed by 40 cycles of 95°C for 30 sec; and 65°C for 45 sec. An ABI 7500 sequence detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used for thermal cycling. This reaction included 2 µl cDNA (200 ng), 2 µl forward primer and 2 µl reverse primer. The primer sequences used for qPCR were:**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGFA</td>
<td>5'-CCA GTC TCA GGG TCC GAG G-3'</td>
<td>5'-TGG TAT GAT TGT GTC TCC ACC-3'</td>
</tr>
<tr>
<td>GAPDH</td>
<td>5'-TCC TCG ATC CCG ACC CAT ATC A-3'</td>
<td>5'-GCT CAT TCA CCA GGT GCC AGC-3'</td>
</tr>
<tr>
<td>U6</td>
<td>5'-ACA CCA GCA CAG CTA TGC TAT A-3'</td>
<td>5'-CAT GAG TGC CTT TCC ACT TTA-3'</td>
</tr>
<tr>
<td>miR-497</td>
<td>5'-CCA GTC TCA GGG TCC GAG G-3'</td>
<td>5'-TGG TAT GAT TGT GTC TCC ACC-3'</td>
</tr>
</tbody>
</table>

**Cell transfection and co-transfection (with luciferase reporter constructs, as described subsequently) were performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. After transfection for 4-6 h, cell culture medium was replaced with RPMI-1640 supplemented with 10% FBS.**

**Cell migration and invasion assays.** The cell migration and invasion assays were performed using Transwell chambers with 8-µm pores (Corning Incorporated, Corning, NY, USA). The Transwell chambers were coated with Matrigel matrix (BD Biosciences, Franklin Lakes, NJ, USA) for 15 min. Following a 24-h transfection with miR-497 or NC, transfected cells were collected and resuspended in culture medium, and 3,000 transfected cells in 100 µl medium were seeded into each well in 96-well plates. Following various incubation times (24-96 h), cells were treated with CCK-8 reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), according to manufacturer's protocol. In brief, 10 µl CCK-8 assay solution was added to each well and incubated in at 37°C for 2 h. Absorbance at 450 nm was detected using the Thermo Scientific Microplate Reader (Thermo Fisher Scientific, Inc.). Each sample was analyzed in triplicate.

**Cell Counting Kit-8 assay.** Following a 24-h transfection with miR-497 or NC, transfected cells were collected and resuspended in culture medium, and 3,000 transfected cells in 100 µl medium were seeded into each well in 96-well plates. Following various incubation times (24-96 h), cells were treated with CCK-8 reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), according to manufacturer's protocol. In brief, 10 µl CCK-8 assay solution was added to each well and incubated in at 37°C for 2 h. Absorbance at 450 nm was detected using the Thermo Scientific Microplate Reader (Thermo Fisher Scientific, Inc.). Each sample was analyzed in triplicate.

**Bioinformatic predication.** The potential targets of miR-497 were analyzed using miRanda (http://www.microrna.org) and TargetScan (http://www.targetscan.org/).
Western blot analysis. Following a 72-h transfection, protein was extracted from transfected cells (miR-497 and NC) using RIPA lysis buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% Na-deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM phenylmethylsulfonyl fluoride; 1 µg/ml each of aprotinin, leupeptin, pepstatin; 1 mM Na3VO4; 1 mM NaF). Protein concentration was detected using a bicinchoninic acid assay kit (Beyotime Institute of Biotechnology). Subsequently, equal amounts of protein were separated by 10% SDS-PAGE (Bioworld Technology, Inc., St. Louis Park, MN, USA) and electro-transferred to polyvinylidene difluoride membranes (Beyotime Institute of Biotechnology). The membranes were blocked with 5% non-fat milk for 1 h at room temperature, and then incubated at 4°C overnight with a mouse anti-human VEGFA monoclonal primary antibody (dilution, 1:1,000; cat no. ab155944; Abcam, Tokyo, Japan) and mouse anti-human β-actin monoclonal primary antibody (dilution, 1:1000; cat no. sc-130,065; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Subsequently, the membranes were incubated with a corresponding horseradish peroxidase-conjugated secondary antibody (dilution, 1:5,000; cat no. sc-2005; Santa Cruz Biotechnology, Inc.) in TBS with Tween-20 (Beyotime Institute of Biotechnology). The bands were detected using an enhanced chemiluminescence solution (Pierce; Thermo Fisher Scientific, Inc.) and imaged using the FluorChem imaging system (Alpha Innotech, San Leandro, CA, USA). Protein expression was quantified using Quantity One software (Bio-Rad Laboratories, Inc., Hercules, CA, USA). β-actin was used as the internal control. This assay was repeated three times.

Dual-Luciferase reporter assay. In order to explore whether VEGFA was a direct target of miR-497, a Dual-Luciferase Reporter Assay (Promega Corporation, Madison, WI, USA) was performed. Cells were transfected with miR-497 mimics or NC and co-transfected with pGL3 Luciferase Reporter Vectors (Promega Corporation) containing wild-type (Wt) or mutated (Mut) 3'-UTR sequences of VEGFA (pGL3-VEGFA-3'-UTR-Wt and pGL3-VEGFA-3'-UTR-Mut, respectively). After 48 h, Dual-Luciferase Reporter Assays were performed to detect firefly and Renilla luciferase activities. Renilla luciferase activities were evaluated as an internal control. Each sample was assayed in triplicate.

Statistical analysis. Data are presented as the mean ± standard deviation of at least three independent experiments, and were statistically analyzed using two-tailed Student’s t test or one-way analysis of variance with SPSS 16.0 statistical software (SPSS, Inc., Chicago, IL, USA). Student-Newman-Keuls method was used to compare between two groups in multiple groups. Two-tailed P<0.05 was considered to indicate a statistically significant difference.

Results

miR-497 expression is downregulated in retinoblastoma tissues and cell lines. RT-qPCR was performed to evaluate miR-497 expression in 23 retinoblastoma tissues and 5 normal retinal tissues. As shown in Fig. 1A, miR-497 was significantly downregulated in retinoblastoma tissues compared with in normal retinal tissues (P<0.05). In addition, the present study examined the expression levels of miR-497 in Y79 and WERI-Rb-1 retinoblastoma cell lines. The results revealed that miR-497 was also downregulated in Y79 and WERI-Rb-1 cell lines in comparison with 5 normal retinal tissues (P<0.05; Fig. 1B). Furthermore, the expression levels of miR-497 in Y79 and WERI-Rb-1 cells following transfection with miR-497 mimics or NC were evaluated. As shown in Fig. 1C,
miR-497 was upregulated in the miR-497 mimic transfectants compared with the NC transfectants (P<0.05).

**miR-497 suppresses cell proliferation in Y79 and WERI-Rb-1 cells.** A CCK-8 assay was performed to assess the role of miR-497 in retinoblastoma cell proliferation. As presented in Fig. 2, restoration of miR-497 via transfection with mimics significantly suppressed Y79 and WERI-Rb-1 cell proliferation after 72 and 96 h (P<0.05). After 96 h, cell proliferation was decreased by 30.48±5.7% in miR-497-transfected Y79 cells and 26.21±4.5% in miR-497-transfected WERI-Rb-1 cells compared with the NC-transfected cells (P<0.05).

**miR-497 suppresses cell migration and invasion in Y79 and WERI-Rb-1 cells.** To investigate the effect of miR-497 on cell migration, Y79 and WERI-Rb-1 cells transfected with miR-497 mimics or NC were seeded into Transwell chambers. Using a Transwell chamber coated with Matrigel matrix, the effect of miR-497 on cell invasion was also investigated. As presented in Fig. 3, in the two cell lines, the percentages of migrated and invaded cells were decreased in cells transfected with miR-497 compared with cells transfected with NC (all P<0.05).

**VEGFA is a potential direct target gene of miR-497 in vitro.** Accumulating studies have suggested that miRNAs exert
their functions by directly regulating target mRNA expression levels (20). Thus, in order to identify the target gene of miR-497, miRanda (http://www.microrna.org) and TargetScan (http://www.targetscan.org/) were used. As presented in Fig. 4A, VEGFA was identified as a potential direct target of miR-497; the analysis revealed that position 276-283 of the VEGFA 3'-UTR comprised a region matching the miR-497 seed sequence.

To investigate the effect of miR-497 on VEGFA expression, miR-497 mimics were transfected into Y79 and WERI-Rb-1 cells. The results demonstrated that forced expression of miR-497 significantly decreased VEGFA expression at the mRNA and protein levels (Fig. 4B and C; P<0.05).

To confirm that VEGFA was a direct target of miR-497, Y79 and WERI-Rb-1 cells were co-transfected with miR-497
mimics or NC, and PGL3-VEGFA-3'-UTR-Wt or PGL3-VEGFA-3'-UTR-Mut. It was revealed that miR-497 mimics suppressed the luciferase activity of PGL3-VEGFA-3'-UTR-Wt but not PGL3-VEGFA-3'-UTR-Mut in Y79 and WERI-Rb-1 cells (Fig. 4D; P<0.05). Taken together, these results suggest that VEGFA is directly targeted by miR-497 in vitro.

Discussion

miR-497, a member of miR-15/16/195/424/497 family, is located on chromosome 17p13.1 (21). The loss or deletion of chromosome 17p13.1 has been demonstrated in various types of cancer, indicating that miR-497 may be downregulated in cancer due to genomic DNA loss or deletion (22-24). An increasing number of previous studies have demonstrated that the expression level of miR-497 is downregulated in numerous cancer types, including renal cancer (25), pancreatic cancer (26), hepatocellular carcinoma (27), endometrial cancer (28), nasopharyngeal carcinoma (29), and breast (30), colorectal (21), gastric (31) and prostate cancer (32). In renal cancer, miR-497 was shown to be significantly downregulated, and the low miR-497 expression level was associated with tumor stage, histological grade and lymph node metastases (25). In pancreatic cancer, the expression level of miR-497 was significantly decreased in comparison with adjacent non-tumorous tissues. Furthermore, downregulation of miR-497 was an independent adverse prognostic factor for pancreatic cancer and was recommended for investigation as a prognostic marker (26). Guo et al (31) revealed that miR-497 was also downregulated in the plasma of bladder cancer patients compared with healthy patients, which indicated that miR-497 expression in the plasma could be explored as a promising novel circulating biomarker. However, to the best of our knowledge, the expression level of miR-497 has not been previously studied in retinoblastoma. The present study demonstrated that miR-497 was downregulated in retinoblastoma tissues and cell lines, and provides further evidence regarding the expression level of miR-497 in cancer.

miR-497 has been verified as a tumor suppressor in cancer. In prostate cancer, miR-497 has been demonstrated to regulate the nuclear factor-κB (NF-κB) signaling pathway by targeting inhibitor of NF-κB kinase subunit β, decreasing cell growth, migration and invasion (33). In lung cancer, miR-497 inhibited cell growth by downregulation of cyclin E1 (CCNE1) (24). In ovarian cancer, upregulation of miR-497 significantly decreased angiogenesis via blockade of VEGFA (34). In human cervical carcinoma, exogenous expression of miR-497 suppressed cell proliferation, migration and invasion through downregulation of insulin-like growth factor 1 receptor (IGF-1R) and CCNE1 (35,36). Furthermore, in colorectal cancer, ectopic expression of miR-497 targeted IGF-1R to suppress cell survival, growth and invasion, and to enhance cell sensitivity to apoptosis (21). The present study revealed that miR-497 inhibited cell proliferation, migration and invasion via blockade of VEGFA. Taken together, these findings indicate that miR-497 could be developed as a novel molecular marker and targeted therapy in the future. Exogenous expression of miR-497 or provision of analogous pharmaceutical compounds exogenously may be effective therapies for cancers resulting from the overexpression of miR-497's target oncogenic transcripts.

Identification of miR-497 target genes is essential for understanding its functions in retinoblastoma carcinogenesis and progression, and for exploring novel targeted therapies for retinoblastoma. In the present study, an important molecular mechanism involving miR-497 and VEGFA was demonstrated in vitro. Firstly, miRanda and TargetScan predicted that VEGFA was a potential target of miR-497. Secondly, RT-qPCR and western blot analysis revealed that miR-497 decreased VEGFA expression at the mRNA and protein levels. Finally, the Dual-Luciferase reporter assay revealed that miR-497 directly targeted the VEGFA 3' UTR. These findings indicate that miR-497 contributed to retinoblastoma carcinogenesis and progression via directly targeting VEGFA.

VEGFA is a 35-45 kDa heparin-binding glycoprotein and a central mediator of inflammation and angiogenesis (37). Increasing evidence has suggested that VEGFA is upregulated in numerous cancer subtypes, including retinoblastoma (38). VEGFA has been revealed to be involved in vasculogenesis, angiogenesis, cell proliferation, migration, invasion and tumor angiogenesis (39-41). A number of anti-VEGFA monoclonal antibodies that specifically bind to the VEGFA receptor to inhibit VEGFA signaling are in development at present, and certain of these antibodies are currently in clinical trials for cancer treatment (37). Therefore, regarding its cancer-associated functions, VEGFA is worthy of attention as a potential target for inhibition in retinoblastoma. The present study revealed that miR-497 inhibited proliferation, migration and invasion of retinoblastoma cells by negative regulation of VEGFA. This suggested that miR-497 could be investigated as a targeted therapy for retinoblastoma.

VEGFA has been demonstrated to be regulated by multiple miRNAs in cancer. For example, in lung cancer, miR-126 was demonstrated to suppress lung cancer cell proliferation via blockade of VEGFA (42). In hepatocellular carcinoma, miR-146a was shown to be downregulated and significantly associated with liver cancer metastasis, whereas its upregulation inhibited hepatocellular carcinoma cell invasion and metastasis by repression of VEGFA expression (43). In breast cancer, ectopic expression of miR-185 decreased cell growth and invasion and contributed to breast cancer formation by directly targeting VEGFA (44). In osteosarcoma, miR-145 and miR-410 targeted VEGFA to suppress cell growth and metastasis (37,45). The present study verified that miR-497 negatively regulated the expression level of VEGFA to inhibit cell proliferation, migration and invasion in retinoblastoma. Taken together, these findings indicate that an miR-497/VEGFA-based targeted therapy may be a novel therapy for retinoblastoma.

In summary, the present study revealed that miR-497 was downregulated in retinoblastoma, and that forced expression of miR-497 significantly decreased cell proliferation, migration and invasion in retinoblastoma cells by directly targeting VEGFA. These findings indicated that miR-497 served an important role in inhibiting retinoblastoma carcinogenesis and progression by targeting VEGFA and should be investigated as a potential novel targeted therapy for retinoblastoma.
References


